

DAFTAR PUSTAKA

- Babjuk M, Böhle A, Burger M, et al. 2016. Guideline on non-muscle invasive bladder cancer (TaT1 and Cis). In : European Association of Urology Guidelines.
- Barabas K, Milner R, Lurie D, et al. 2008. Cisplatin : a review of toxicities and therapeutic applications. *Vet & Comp Oncol* ;6(1):1-18.
- Bellmunt J. 2012. New therapeutic challenges in advanced bladder cancer. *Semin Oncol*, 39: 598.
- Burger M. 2013. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*, 63 : 234-41.
- Callus BA dan Vaux DL. 2007. Caspase inhibitors: viral, cellular and chemical. *Cell Death Differ* 14, pp. 73.
- Costantini C dan Millard F. 2011. Update on chemotherapy in the treatment of urothelial carcinoma. *The Scientific World J*, 11 : 1981-94.
- Currie CJ, Poole CD, Jenkins-Jones S, et al. 2012. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. *Diabetes Care*. 35: 299-304.
- Dalva-Aydemir S, Bajpai R, Martinez M, et al. 2015. Targetting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. *Clinical Cancer Research*. 21:1161-1171.
- David B dan Samadi. 2008. Anatomy of bladder from www.roboticoncology.com
- Edge SB, Byrd DR, Compton CC, et al. eds. 2010. TNM classification of malignant tumors, *AJCC Cancer Staging Manual*, 7th edition. New York: Springer.

- Evans JM, Donnelly LA, Emslie-Smith AM, et al. 2005. Metformin and reduced risk of cancer in diabetic patients. *British Medical Journal*.330; 1304-1305.
- Foretz M dan Viollet B. 2011. Regulation of hepatic metabolism by AMPK. *J Hepatol*, 54:827–829.
- Graham G, Punt J, Arora M, et al. 2012. Clinical pharmacokinetics of metformin. *Clin Pharmacokinet*, 50:81–98.
- Gupta S dan Mahipal A. 2013. Role of systematic chemotherapy in urothelial urinary bladder cancer. *Cancer Kontrol* 20:200-210.
- Hall MC dan Chang SS. 2007. Bladder cancer, Guidelines for the management of nonmuscle invasive bladder cancer : (Stage Ta, T1, Tis).
- Hanahan D dan Weinberg RA. 2011. Hallmarks of cancer: The next generation. *Cell*. 144:646-674.
- Herr HW, Dotan Z, Donat SM, et al. 2007. Defining optimal therapy for muscle invasive bladder cancer. *J Urol* 177: 437-443.
- Iliopoulos D, Hirsch HA, Struhl K.. 2011. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenograft involving multiple cancer cell types. *Cancer Research*. 71: 3196-3201.
- James ND. 2012. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *N Engl J Med*, 366 (16) : 1477-88.
- Juffs HG, Moore MJ, Tannock IF. 2002. The role of systematic chemotherapy in the management of muscle-invasive bladder cancer. *Lancet Oncol* 3: 738-747.

- Kim YD, Park KG, Lee YS, et al. 2008. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. *Diabetes*, 57:306–314.
- Kordes S, Pollak MN, Zwinderman AH, et al. 2015. Metformin in patients with advanced pancreatic cancer: a double-blind, randomized, placebo-controlled phase 2 trial. *Lancet Oncology*; 16:839-847.
- Kumar. 2013. *Robbins Basic Pathology*, 9 ed. Saunders : Elsevier Inc.
- Liu Qiuli, Yuan Wenqiang, Tong Dali, et al.. 2016. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. www.impactjournals.com. *Oncotarget*, vol.7, no.19: 28235-46.
- Minematsu T dan Giacomini KM. 2011. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. *Mol Cancer Ther*, 10:531–539.
- Muller J, Lips KS, Metzner L, et al. 2005. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). *Biochem Pharmacol*;70:1851–1860.
- Nayan M, Bhindi B, Yu JL, et al. 2015. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial karsinoma of the bladder. *Urol Oncol*;33:e7-e13.
- Nies AT, Hofmann U, Resch C, et al. 2011. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). *PLoS One*; 6 : 22163.

- Peng Mei, Su Qiongli, Zeng Qing, et al. 2016. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. www.impactjournals.com. *Oncotarget*, vol.7, no.8: 9102-17.
- Ploeg M, Aben KKH, Kiemeny LA. 2009. The present and future burden of urinary bladder cancer in the world. *World J Urol*, 27 : 289-93.
- Rojas J, Chávez-Castillo M, Torres W, et al. 2014. Metformin in Cancer: Chemical Pathways for Tumoral Control Independent of Amp-Dependent Kinase. *J Endocrinol Diabetes Obes* 2(2): 1036.
- Ruiter R, Visser LE, van Herk-Sukel MP, et al. 2012. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population –based follow-up study. *Diabetes Care*; 35: 119-124.
- Serretta V, Morgia G, Altieri V, et al. 2010. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. *British Journal of Urology International*. 106:212-217.
- Siegel RL, Miller KD, Jemal A. Cancer statistics. 2015. *CA: A Cancer Journal for Clinicians*, 65:5-29.
- Somogyi A, Stockley C, Keal J, et al. 1987. Reduction of metformin renal tubular secretion by cimetidine in man. *Br J Clin Pharmacol*, 23:545–551.
- Stenberg CN, Bellmunt J, Sonpavde G, et al. 2013. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. *European Urology*. 63:58-66.
- Sternberg CN, Skoneczna IA, Castellano D, et al. 2013. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder

cancer: a randomized, active-controlled, phase III trial (CILAB). *Oncology*; 85: 208-215.

Stenzl A. 2011. Treatment of muscle-invasive and metastatic bladder cancer : update of the EAU guidelines. *Eur Urol*, 59 : 1009-18.

Takane H, Shikata E, Otsubo K, et al. 2008. Polymorphism in human organic cation transporters and metformin action. *Pharmacogenomics*. 9:415–422.

Tseng CH. 2014. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. *Acta Diabetol*. 51:295-303.

Tzvetkov MV, Vormfelde SV, Balen D, et al. 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. *Clin Pharmacol Ther* ;86:299–306.

Vita De, Hellman, Rossenberg. 2011, *Platinum Analogs: cancer principles and practice of Oncology*, Lippincot Williams Wilkins; 35: 386-391.

Von der MaaseH. 2005. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J Clin Oncol*, 23: 4602.

Wang D dan Wu X.2015. In vitro and in vivo targetting of bladder carcinoma with metformin in combination with cisplatin. *Oncol. Letters*. 10: 975-981.

Wein AJ, Kavoussi LR, Partin AW, et al. 2016. *Campbel-Walsh Urology*, 11th edition. Philadelphia : Elsevier.

Yafi FA dan Kassouf W. 2009. Radical cystectomy is the treatment of choice for invasive bladder cancer. *Canadian Urol Association J*, 3 (5) : 409-12.

Zhang L, Yang N, Katsaros D, et al. 2003. The Oncogene phosphatidylinositol 3'kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. *Cancer Res*, 63:4225- 4235.

Zhang T, Guo P, Zhang Y, et al. 2013. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells invitro and in vivo. *Int J Mol Sci* ;14:24603-18.

Zhou M, Xia L, Wang J. 2007. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. *Drug Metab Dispos.*, 35:1956–1962.